All > Anemia

AND017 for Kidney Anemia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Kidney AnemiaAND017 - Drug
Eligibility
20 - 74
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying a drug to see if it is safe and effective for patients with non-dialysis chronic kidney disease.

Eligible Conditions
  • Kidney Anemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
M281
1
Mitapivat
1
Experimental: SDX

Study Objectives

2 Primary · 15 Secondary · Reporting Duration: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose

Week 10
Change in hemoglobin levels from baseline to the mean of weeks 10-13
Week 2
To assess changes in the levels of PD indicator - EPO
To assess changes in the levels of PD indicator - hepcidin
Week 3
Therapeutic procedure
To assess iron utilization parameter during treatment - transferrin level
To assess iron utilization parameter during treatment - transferrin saturation (TSAT)
To assess iron utilization parameters during treatment - ferritin
To assess iron utilization parameters during treatment - serum iron
Week 13
Change from baseline in Hb
Hemoglobin, Sickle
Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit
Percentage of responder patients
Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL
Up to 17 weeks
Safety Evaluations
Week 5
Hb response to treatment during Period 1
Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing
Week 13
Cumulative incidence of lack of response over the entire treatment period

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

2
M281
2
Mitapivat
2
Experimental: SDX

Trial Design

4 Treatment Groups

AND017 Dose A
1 of 4
AND017 Dose B
1 of 4
AND017 Dose C
1 of 4
Placebo
1 of 4

Experimental Treatment

Non-Treatment Group

88 Total Participants · 4 Treatment Groups

Primary Treatment: AND017 · Has Placebo Group · Phase 2

AND017 Dose A
Drug
Experimental Group · 1 Intervention: AND017 · Intervention Types: Drug
AND017 Dose B
Drug
Experimental Group · 1 Intervention: AND017 · Intervention Types: Drug
AND017 Dose C
Drug
Experimental Group · 1 Intervention: AND017 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AND017
2020
Completed Phase 1
~20

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and at week 3, 6, 9, 12, 14, and 28 days after the last dose

Who is running the clinical trial?

Kind Pharmaceuticals LLCLead Sponsor
4 Previous Clinical Trials
273 Total Patients Enrolled
Yusha Zhu, MD PhDStudy DirectorKind Pharmaceuticals LLC
3 Previous Clinical Trials
153 Total Patients Enrolled

Eligibility Criteria

Age 20 - 74 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have chronic kidney disease, not receiving dialysis, with an eGFR <60 mL/min/1.
You have an abnormal result for the screening test.
You have serum folate and vitamin B12 levels that are normal at screening test.
If your total bilirubin is >1.

Who else is applying?

What state do they live in?
North Carolina100.0%
How old are they?
65+100.0%
What site did they apply to?
Metrolina Nephrology Associates100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria50.0%
Met criteria50.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top